呼吸介入治疗医疗器械研发商融和医疗完成近亿元B轮融资，启明创投领投

Core Insights - Ronghe Medical has completed nearly 100 million yuan in Series B financing, led by Qiming Venture Partners, to accelerate the clinical promotion and market expansion of its innovative "real-time electromagnetic navigation bronchial rheoplasty" technology for chronic obstructive pulmonary disease (COPD) treatment [2] Group 1: Company Overview - Ronghe Medical Technology (Zhejiang) Co., Ltd. was established in July 2022 and has developed the Breeze One® real-time electromagnetic navigation pulsed electric field ablation system, which received FDA breakthrough device designation in April 2025, marking a significant milestone for China in the respiratory intervention treatment field [2] Group 2: Technology Advantages - The system integrates three-dimensional visual electromagnetic navigation technology, akin to a "bronchial GPS" for doctors, significantly shortening the clinical learning curve and enhancing surgical precision and efficiency [3] - The technology directly ablates abnormal mucus-secreting goblet cells using pulsed electric field technology, reducing phlegm production at the source and alleviating symptoms such as cough and breathing difficulties, thus shifting treatment from symptomatic management to root cause resolution [4] - It employs a non-thermal mechanism to avoid thermal and mechanical damage to surrounding blood vessels, nerves, and cartilage, significantly enhancing surgical safety [5] Group 3: Future Directions - Ronghe Medical aims to continue focusing on cutting-edge life sciences, deepening the expansion and integration of its core technology matrix, and developing original medical device solutions with significant clinical value [6]